Provided is an integrated device for preparing magnesium hydride powder and a method for preparing magnesium hydride powder. The device comprises a heating chamber for heating a magnesium-based metal material to produce metal droplets; a powder-making chamber comprising an atomizing means used for atomizing the metal droplets which are then cooled to form a metal powder; and a reaction chamber used for performing a hydrogenation reaction on the metal powder to form the magnesium hydride powder. The device is an integrated structure monolithic with a simple structure and a convenient operation; and the entire process of preparing magnesium hydride powder can be completed in this single device and can realize automated control. The preparation method is simple and easy to operate and produces a product that has a moderate size, uniform particles, and excellent performance.

A thermoelectric conversion element includes: a thermoelectric conversion material portion composed of a material having a band gap; a first electrode disposed in contact with the thermoelectric conversion material portion; a second electrode disposed in contact with the thermoelectric conversion material portion and disposed to be separated from the first electrode; and a sealing portion that seals the thermoelectric conversion material portion. A partial pressure of oxygen in a region surrounding the thermoelectric conversion material portion is maintained by the sealing portion so as to be lower than a partial pressure of oxygen in an external air.

The present invention provides a method for the manufacture of transition metal oxide fine particles, the method comprising the steps of: heating a strong-alkaline aqueous solution while stirring same; adding to and dissolving in the heated strong-alkaline aqueous solution a transition metal oxide; adding a strong-acid aqueous solution to the strong alkaline aqueous solution in which the transition metal oxide is dissolved, while stirring same, thereby re-dissolving a solid generated at the interface between the strong-alkaline aqueous solution and the strong-acid aqueous solution; adjusting the pH of the mixed aqueous solution resulting from mixing the strong-alkaline aqueous solution and the strong acid aqueous solution, through adjustment of the adding rate and amount of the strong-acid aqueous solution, to precipitate transition metal oxide fine particles; and separating the transition metal oxide fine particles from the mixed aqueous solution and sequentially washing, drying, and thermally treating the separated transition metal oxide fine particles.

Certain aspects of the technology disclosed herein include an apparatus and method for forming nanoparticles. The method includes a mechanical milling process induced by aerodynamic, centrifugal, and centripetal forces and further augmented by ultrasound, magnetic pulse, and high voltage impact. A nanoparticle mill having an atmospheric and luminance controlled environment can form precisely calibrated nanoparticles. A nanoparticle mill can include first aerodynamic vane configured to rotate around a central axis of the nanoparticle mill in a first direction, and a second aerodynamic vane configured to rotate around the central axis in a second direction. An aerodynamic shape of an aerodynamic vane can be configured to cause particles within the nanoparticle mill to flow around the aerodynamic vane. The nanoparticle mill can include a primary product line, a nanoparticle sampling line, a particle programming array, a solidifying chamber, or any combination thereof.

A silver ink including silver particles and a protective agent containing at least one amine compound dispersed in a dispersion medium containing, as a main solvent, a solvent having a vapor pressure at 20° C. of 40 mmHg or less and a vapor pressure at 70° C. of 0.09 mmHg or more, in an amount of 80% or more on a mass basis relative to the total dispersion medium. The amine compound has a mass average molecular weight of 115 or less, and the total amount of the amine compound is 1 part by weight or more and 14 parts by weight or less per 100 parts by weight of the silver particles. The silver ink has a moisture content of 500 ppm or more and 50,000 ppm or less and enables a practical metal film to be formed even through calcination at a low temperature of 70° C. or less.

The present disclosure relates to a metal particle-containing composition contains at least one thermosetting resin (R), a hardening agent (H), and at least three types of metal particles (P) different from one another. The metal particles (P) contain a solder alloy particle (P1) containing a tin alloy containing at least one metal (A), wherein the metal (A) is a metal that forms a eutectic crystal with tin at a eutectic temperature of 200° C. or lower, at least one metal particle (P2) containing a metal (B) having a melting point exceeding 420° C. in a bulk, the metal particle (P2) having a melting point higher than a solidus temperature of the solder alloy particle (P1), and at least one metal particle (P3) containing a metal (C) that forms an intermetallic compound with a metal contained in the solder alloy particle (P1).

Provided is a soft magnetic powder that can produce a dust core having excellent magnetic properties. The soft magnetic powder has a chemical composition, excluding inevitable impurities, represented by a composition formula of Fe.sub.aSi.sub.bB.sub.cP.sub.dCu.sub.eM.sub.f, where the M is at least one element selected from the group consisting of Nb, Mo, Zr, Ta, W, Hf, Ti, V, Cr, Mn, C, Al, S, O, and N, 79 at %≤a≤84.5 at %, 0 at %≤b<6 at %, 0 at %<c≤10 at %, 4 at %<d≤11 at %, 0.2 at %≤e≤0.53 at %, 0 at %≤f≤4 at %, a+b+c+d+e+f=100 at %, a particle size is 1 mm or less, and a median of circularity of particles constituting the soft magnetic powder is 0.4 or more and 1.0 or less.

An aluminum alloy material has a composition containing 3% by mass or more and 10% by mass or less of Fe and the balance of Al and incidental impurities, and a structure including a matrix and a compound. The matrix is composed mainly of Al, the compound contains Al and Fe, and a relative density is 85% or more. In any cross section, the matrix has an average crystal grain size of 1,100 nm or less, and the compound has an average major-axis length of 100 nm or less.

The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution.

The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions. In one embodiment, the condition is mediated by MIF (macrophage migration inhibiting factor).

The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution.

The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions. In one embodiment, the condition is mediated by MIF (macrophage migration inhibiting factor).